Browse studies

Find your next paid study

103 recruiting studies matching your filters

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of Resmetirom for the Treatment of Metabolic Dysfunction- Associated Steatotic Liver Disease (MASLD) in People Living With Human Immunodeficiency Virus (HIV)

The purpose of this research study is to test the safety and effectiveness of the study drug, resmetirom, in participants with MASLD and HIV. This is a researc…

MASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseHIV (Human Immunodeficiency Virus)

Estimated

~$10 – $8,750

Naga P. ChalasaniNCT07143968

Measuring Patient Reported Needs in Outpatient Liver Disease Management

This prospective study aims to assess health-related social needs (HRSNs) among patients with chronic liver disease (CLD) receiving outpatient care at Indiana …

Chronic Liver DiseaseCirrhosis, Liver

Estimated

~$10 – $750

Indiana UniversityNCT07191886

Phase 3

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa in Participants With Biopsy-Confirmed F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-1)

The purpose of this study is to assess the safety and efficacy of efimosfermin alfa in the resolution of steatohepatitis and improvement of liver-related clini…

Non-alcoholic Fatty Liver Disease

Estimated

~$10 – $7,500

GlaxoSmithKlineNCT07221227

Supplementation of Pomegranate Dietary Supplements and Characterization of Urolithin Metabotypes in Patients With Alcohol Use Disorder (AUD) and Alcohol-associated Liver Disease (ALD)

The goal of this project is to determine an individual's ability to generate active gut microbial metabolites called urolithins upon consumption of pomegranate…

Alcohol Use DisorderAlcohol-associated Liver DiseaseAlcoholic Cirrhosis+1 more

Estimated

~$10 – $750

University of LouisvilleNCT07678567

Phase 1

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Study of Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers

Background: Drinking alcohol can lead to swelling and injury in the liver. Long-term heavy drinking may lead to liver disease. Researchers want to study the r…

Alcohol Associated Liver DiseaseHeavy Drinking Behavior

Estimated

~$10 – $5,625

National Institute on Alcohol Abuse and Alcoholism (NIAAA)NCT04781322

Phase 2

Effect of Ketone Esters on Liver Fat and Metabolic Function in Adolescents and Young Adults With Overweight/Obesity and MASLD

The goal of this clinical trial is to determine whether ingestion of a ketone ester drink helps improve liver health and blood glucose control. Ketones are a t…

MASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseObesityOverweight (BMI > 25)

Estimated

~$10 – $6,250

Washington University School of MedicineNCT07097506

Functional Assessment in Liver Transplant Candidates (FrAILT) Study

This will be a prospective cohort study of patients with liver disease. Subjects will undergo geriatric assessments of frailty, functional status, and disabili…

End Stage Liver Disease

Estimated

~$10 – $675

University of California, San FranciscoNCT03228290

Prospective Observational Study of Primary Sclerosing Cholangitis (PSC) in Children

Primary sclerosing cholangitis (PSC) is a rare liver disease that damages the liver's bile ducts. Bile ducts are tiny tubes that carry bile from the liver to t…

Primary Sclerosing CholangitisLiver DiseasesCholangitis, Sclerosing

Estimated

~$10 – $1,125

Arbor Research Collaborative for HealthNCT04181138

Phase 1

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Two Doses of ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)

This study is researching an experimental drug called ALN-CIDEB, also referred to as "study drug". The study is focused on participants with metabolic dysfunct…

Metabolic Dysfunction-Associated Steatotic Liver DiseaseMetabolic Dysfunction-Associated Steatohepatitis

Estimated

~$10 – $8,750

Regeneron PharmaceuticalsNCT06836609

Phase 2

A Phase 2, Randomized, Double-blinded, Placebo-controlled Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabol…

Metabolic Dysfunction-Associated SteatohepatitisNon-alcoholic Fatty Liver Disease

Estimated

~$10 – $7,500

GlaxoSmithKlineNCT06920043

Phase 1

Human Models of Selective Insulin Resistance: Diazoxide, Part I

The goal of this clinical trial is to compare a one-week course of diazoxide (2 mg/kg per dose x 14 doses) and placebo in people with obesity and insulin resis…

HyperinsulinemiaInsulin ResistanceNon-Alcoholic Fatty Liver Disease+2 more

Estimated

~$10 – $6,250

Columbia UniversityNCT07403604

Observational

Integrating Veteran-Centered Care for Advanced Liver Disease (I-VCALD)

Advanced liver disease is a serious illness that disproportionately affects Veterans, many of whom hope for curative liver transplantation. However, too few re…

Liver Diseases

Estimated

~$10 – $5,625

VA Office of Research and DevelopmentNCT06068491